Search by Drug Name or NDC

    NDC 00074-2100-70 Skyrizi 150 mg/mL Details

    Skyrizi 150 mg/mL

    Skyrizi is a SUBCUTANEOUS INJECTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by AbbVie Inc.. The primary component is RISANKIZUMAB.

    Product Information

    NDC 00074-2100
    Product ID 0074-2100_7718dd85-622c-478e-ae9b-91e14a1373c6
    Associated GPIs 9025057070D520
    GCN Sequence Number 082261
    GCN Sequence Number Description risankizumab-rzaa PEN INJCTR 150 MG/ML SUBCUT
    HIC3 L1A
    HIC3 Description ANTIPSORIATIC AGENTS,SYSTEMIC
    GCN 49591
    HICL Sequence Number 045699
    HICL Sequence Number Description RISANKIZUMAB-RZAA
    Brand/Generic Brand
    Proprietary Name Skyrizi
    Proprietary Name Suffix n/a
    Non-Proprietary Name risankizumab-rzaa
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form INJECTION
    Route SUBCUTANEOUS
    Active Ingredient Strength 150
    Active Ingredient Units mg/mL
    Substance Name RISANKIZUMAB
    Labeler Name AbbVie Inc.
    Pharmaceutical Class Interleukin-23 Antagonist [EPC], Interleukin-23 Antagonists [MoA]
    DEA Schedule n/a
    Marketing Category BLA
    Application Number BLA761105
    Listing Certified Through 2025-12-31

    Package

    NDC 00074-2100-70 (00074210070)

    NDC Package Code 0074-2100-70
    Billing NDC 00074210070
    Package 1 SYRINGE in 1 CARTON (0074-2100-70) / 1 mL in 1 SYRINGE
    Marketing Start Date 2021-04-26
    NDC Exclude Flag N
    Pricing Information N/A